Table 1.
Basic Characteristics of Studies Included in Meta-Analysis.
| Author | Year | Country | Sample size | Sex (M/F) | Ethnicity | TNM stage | Treatment | Age (years) mean/median (range) | Study design | Cutoff value | Survival analysis | Study duration | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee | 2016 | Korea | 82 | 49/33 | Asian | III-IV | Chemotherapy + targeted therapy | 63.5 | Retrospective | 0.5 | OS, PFS | 2011-2014 | 8 |
| Wu | 2016 | China | 233 | 156/77 | Asian | III-IV | Chemotherapy | 62 (26-85) | Retrospective | 0.54 | OS | 2011-2014 | 7 |
| Hang | 2017 | China | 142 | 92/50 | Asian | III-IV | Chemotherapy | 61 (34-86) | Retrospective | 0.156 | OS | 2009-2014 | 7 |
| Ikeguchi | 2017 | Japan | 43 | 30/13 | Asian | I-III | Surgery | 71.6 (37-88) | Retrospective | 0.04 | OS, DFS | 2006-2015 | 8 |
| Piciucchi | 2017 | Italy | 206 | 112/84 | Caucasian | I-IV | Mixed | 69.9 | Retrospective | 1 | OS | NR | 6 |
| Arima | 2018 | Japan | 142 | 74/68 | Asian | NR | Surgery | 69 (37-90) | Retrospective | 0.34 | OS, PFS | 2004-2014 | 6 |
| Fujiwara | 2018 | Japan | 188 | 115/73 | Asian | I-IV | Surgery | 67 (27-84) | Retrospective | 0.004 | OS, DFS | 2000-2015 | 7 |
| Kim | 2018 | Korea | 302 | 189/113 | Asian | III-IV | Chemotherapy + targeted therapy | 64 (38-83) | Retrospective | 3.85 | OS, PFS | 2004-2016 | 7 |
| Fan | 2019 | China | 595 | 380/215 | Asian | III-IV | Chemotherapy | 62 (33-84) | Retrospective | 0.18 | OS | 2011-2016 | 8 |
| Ikuta | 2019 | Japan | 136 | 76/60 | Asian | I-IV | Surgery | 68 (33-86) | Retrospective | 0.09 | OS | 2005-2017 | 7 |
| Vujic | 2019 | Austria | 202 | NR | Caucasian | NR | Surgery | NR | Retrospective | 0.0003 | OS | 2000-2016 | 6 |
Abbreviations: DFS, disease-free survival; F, female; M, male; NR, not reported; NOS, Newcastle Ottawa scale; OS, overall survival; PFS, progression-free survival.